The National Centre for Expertise of Medicines and Medical Devices of Kazakhstan (NDDA) said in a release on its website on 27 October that its director general, Dauren Dikhanbayev, made a working visit to China in October, one of the key items on whose agenda was discussing the conditions for Chinese manufacturers to enter the markets of Kazakhstan and the Eurasian Economic Union countries.
What events did the Kazakh expertise centre attend in China?
According to NDDA, Dikhanbayev attended the opening ceremonies of the 93rd National Pharmaceutical Trade Fair (PHARMCHINA) and the 94th China International Medical Equipment Fair (CMEF). The two fairs bring together companies in medicines, medical devices, equipment and new medical technologies. As part of the business programme, a themed event, "Medical devices entering the Eurasian Economic Union market: opportunities and pathways", was also held, attended by representatives of regulators, academia, industry associations and companies from Kazakhstan, Russia and China.
What did Chinese pharmaceutical and medical device companies hear?
According to NDDA, Dikhanbayev gave a presentation at the themed event titled "Kazakhstan's experience in regulating access of medical devices and development prospects", describing the main practices in regulating the circulation of medical devices in Kazakhstan and directions for further improvement. Participants discussed harmonisation of regulatory requirements, the conditions for entering the markets of the Eurasian Economic Union countries and possibilities for industrial cooperation.
A separate closed meeting focused on Chinese pharmaceutical and medical device manufacturers entering the Kazakh market. About 25 large Chinese companies attended, chaired by the president of the Beijing Medical Devices Chamber of Commerce. Dikhanbayev described the Kazakh pharmaceutical market, its features and the opportunities it offers foreign manufacturers; representatives of Chinese companies presented their products and business lines, and the participants discussed prospects for future cooperation.
How were the registration requirements explained?
According to NDDA, a round table on Kazakhstan's legislation on the circulation of medicines and medical devices was also held during the visit, explaining to Chinese industry representatives the requirements for national registration of products and other conditions for products to enter the Kazakh market. Note that the release does not list specific registration steps, document lists or processing times; for such details the official rules of the Kazakh competent authority apply.
What else did the delegation visit?
NDDA says that, in addition to the events in Beijing, the Kazakh delegation visited the production sites of pharmaceutical companies in Guangzhou and Shenzhen to learn about their operations and production processes. NDDA says these meetings built professional contacts and discussed practical questions of cooperation with Chinese manufacturers.
Rules related to this news
Frequently asked questions
### Can Chinese pharmaceutical companies already sell directly in Kazakhstan?
The release does not say so. NDDA explained that products need national registration and described other conditions for entering the Kazakh market; whether registration succeeds and when sales can start depends on the outcome for each specific product.
### Which Chinese companies attended this meeting?
NDDA only says that about 25 large Chinese companies attended the closed meeting; it did not publish a list of companies and does not mention any agreement being signed.
### How do Kazakhstan's entry requirements relate to the Eurasian Economic Union?
According to NDDA, the themed event discussed the pathway for medical devices to enter the Eurasian Economic Union market and the harmonisation of regulatory requirements. The release does not give the specific content of the union's common rules.
### Where should I look for information on the registration process?
Start with the news and official explanations on the NDDA website; specific documents and time limits should follow the official rules of the Kazakh competent authority. The release also lists the centre's helpline telephone number and email address, which can serve as an official channel for reference.
Further reading
- More industry and policy news: Kazakhstan investment and projects news section
- Similar pharmaceutical project: BeOne and Kazakhstan's INKAR cooperate on local production of oncology drugs
- Services for companies going abroad: what the Central Asia Jiangsu Center offers to companies going abroad
- Setting up a company entity in Kazakhstan: Kazakhstan company registration services
Sources
- Website of the National Centre for Expertise of Medicines and Medical Devices (NDDA), 27 October: https://www.ndda.kz/news/Kazakhstan_China
The cover image was generated by AI and is not a real photograph.